Calidi Biotherapeutics (CLDI) Leases (2022 - 2025)

Calidi Biotherapeutics has reported Leases for 4 years, with the latest figure at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Leases fell 42.67% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 42.67% YoY), and the FY2025 full-year result was $1.7 million, down 42.67% from the prior year.
• Leases for Q4 2025 stood at $1.7 million, down from $2.0 million in the prior quarter.
• The five-year high for Leases was $4.8 million in Q1 2023, with the low at $193000.0 in Q3 2022.
• Average Leases over 4 years is $2.9 million, with a median of $3.1 million recorded in 2024.
• Year-over-year, Leases soared 2144.04% in 2023 and sank 42.67% in 2025.
• Tracing CLDI's Leases over 4 years: stood at $199000.0 in 2022, then soared by 1946.73% to $4.1 million in 2023, then decreased by 27.96% to $2.9 million in 2024, then slumped by 42.67% to $1.7 million in 2025.
• The last three Leases figures came in at $1.7 million (Q4 2025), $2.0 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.

Peer Comparison